NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment

Read the latest report on NanoViricides here.

NanoViricides NNVC is a drug development company working on a novel nanomedical treatment. It recently updated the world on the status of its long-awaited and now active trials into its lead drug candidate, NV-CoV-2. 

“NV-CoV-2, the Company’s lead drug candidate for the treatment of coronavirus infections including COVID and potentially many cases of long COVID, has entered human clinical trials initiated by the Drug Sponsor Karveer Meditech Pvt. Ltd. India, the Company’s Licensee and co-developer in India,” announced the Company. 

NanoViricides is developing cutting-edge nanomedicine treatments, which use their special nanomicelles’ ability to directly attack and destroy the virus particles. To do this, the nanoviricides mimick the receptor site on the cell to which the virus binds. No matter how many variants develop, this site remains the same, so the virus is unlikely to escape the nanoviricide drug.

The Company’s drug candidate NV-CoV-2 uses the company’s patented nanoviricide platform technology, which uses novel mechanisms to fight COVID-19 and potentially all other  human coronaviruses. 

The Need For A Lasting Coronavirus Treatment

As the company races to develop its leading drug, there remains a significant need to develop safe and lasting treatments for COVID-19 and other coronaviruses. 

It has been estimated that by the end of the four-year period from January 2020 to December 2023, the COVID-19 pandemic will have cost the American economy up to $14 trillion.

Furthermore, it is estimated that 65 million people still suffer from “long COVID,”  the continuation of coronavirus symptoms for months after clinically the infection itself has subsided. Symptoms of long Covid can range from mild to severe, and the case numbers of those with long Covid are continuing to increase. 

Could NV-CoV-2 Be Used For Future Pandemics?

Then there are the risks of other coronaviruses and future pandemics. A prediction from the disease research group Metabiota, says that there is a 47% - 57% likelihood that another pandemic as serious as COVID-19 could occur within the next 25 years. 

This is why NanoViricides believes it is important to develop a drug that is safe and effective for treating a wide range of patients. Its drug candidate NV-CoV-2 has oral formulations for milder cases and an injectable solution for more severe patients. The company is focusing its attention on treatment for COVID-19 for now, but the innovative nanomedicine could even be a broad-spectrum antiviral for treating diseases beyond COVID-19. 

“We believe these clinical trials are an important milestone not only for NanoViricides and Karveer Meditech, India, but also for the advancement of treatments against all viral infections worldwide,” said Dr. Anil Diwan, Ph.D., President and Executive Chairman of the Company, explaining, “NV-CoV-2 is aimed at satisfying the as-yet-unmet medical need of a highly effective broad-spectrum, anti-coronavirus drug that can be used for all patient populations. Moreover, it brings into the clinic a novel platform technology of attacking viruses to develop highly effective antiviral drugs.”

Treatments for COVID-19 currently on the market include Molnupiravir from Merck & Co. MRK, Paxlovid from Pfizer Inc. PFE and Remdesivir from Gilead Sciences, Inc. GILD, though there are problems or limitations with each of these options, and the multi-billion-dollar market remains wide open for a new effective treatment. The overall antiviral market is projected to surpass around $71.1 billion by 2032.

Learn more about how NanoViricides is tackling coronaviruses by visiting its website.

Featured photo by Edward Jenner on Pexels.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.